镭-223用于一线阿比特龙或恩扎卢胺进展后无症状骨转移的转移性去势抵抗性前列腺癌患者:单臂II期试验
EXCAAPE(NCT03002220)为多中心、单臂、开放、非对照IIa期试验,纳入52例一线阿比特龙或恩扎卢胺进展后无症状骨转移的转移性去势抵抗性前列腺癌患者,接受镭-223(223Ra)每月55 kBq/kg体重、最多6剂。中位影像学无进展生存期(rPFS)为5.5个月(95%CI 5.3-5.5),中位总生存期14.8个月(95%CI 11.2-未达到),AR-V7阴性患者总生存期显著优于阳性患者(14.8个月 vs 3.5个月,P<0.01)。作者认为223Ra似乎是合理治疗选择,安全性可接受。
要点
- 中位rPFS为5.5个月(95%CI 5.3-5.5),中位OS为14.8个月(95%CI 11.2-未达到)。
- AR-V7阴性患者中位OS 14.8个月 vs 阳性患者3.5个月,P<0.01。
- 3/4级贫血和血小板减少发生率分别为5.8%和11.5%,耐受性良好。
核心结论
- 作者认为223Ra似乎是转移性去势抵抗性前列腺癌伴无症状骨转移、新型内分泌治疗进展后的合理治疗选择,安全性可接受。
研究设计与样本
- EXCAAPE(NCT03002220)为多中心、单臂、开放、非对照IIa期试验,纳入52例一线阿比特龙或恩扎卢胺进展后无症状骨转移的转移性去势抵抗性前列腺癌患者。
- 患者接受223Ra每月55 kBq/kg体重、最多6剂。
- 主要终点为影像学无进展生存期(rPFS),次要终点包括基于循环肿瘤细胞(CTC)中雄激素受体剪接变异体7(AR-V7)表达的rPFS、总生存期和安全性。
主要发现
- 中位rPFS为5.5个月(95%CI 5.3-5.5)。
- AR-V7阴性CTC患者中位rPFS为5.5个月 vs AR-V7阳性CTC患者2.2个月,P=0.056。
- 中位总生存期为14.8个月(95%CI 11.2-未达到),AR-V7阴性患者14.8个月 vs AR-V7阳性患者3.5个月,P<0.01。
- 3/4级贫血发生率为5.8%,3/4级血小板减少发生率为11.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The paper aims to evaluate the efficacy and safety of 223Ra in patients who progressed after first-line androgen deprivation therapy. PATIENTS AND METHODS: EXCAAPE (NCT03002220) was a multicentre, single-arm, open-label, non-controlled phase IIa trial in 52 patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases who have progressed on abiraterone acetate or enzalutamide, up to six doses of 223Ra (55 kBq/kg of body weight per month). The primary end-point was radiographic progression-free survival (rPFS). Secondary end-points included rPFS based on androgen receptor splice variant 7 (AR-V7) expression in circulating tumour cells (CTCs), overall survival, and safety. RESULTS: Median rPFS was 5.5 months (95% CI 5.3-5.5). Median rPFS of patients with AR-V7(-) CTCs was longer than that of patients with AR-V7(+) CTCs (5.5 versus 2.2 months, respectively; P = 0.056). Median overall survival was 14.8 months (95% CI 11.2-not reached) and was significantly greater for AR-V7(-) patients than for AR-V7(+) patients (14.8 months versus 3.5 months, respectively; P < 0.01). 223Ra was well tolerated; anaemia and thrombocytopenia were the most common grade 3/4 adverse events (5.8% and 11.5%, respectively). CONCLUSIONS: 223Ra seems to be a reasonable treatment for patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases progressing on novel hormonal therapy and had an acceptable safety profile.
引用
- Carles J, Alonso-Gordoa T, Mellado B, et al. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. Eur J Cancer. 2022. PMID: 35981452. doi:10.1016/j.ejca.2022.06.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。